Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149247 · ClinicalTrials.gov registry record · Phase 2
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
A Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06149247: Completed Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides, sponsored by Soligenix.
NCT06149247 is a Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides that has completed, run by Soligenix. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06149247, a Phase 2 study of Cutaneous T-Cell Lymphoma/Mycosis Fungoides, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Primary Outcome
A treatment response is defined as a ≥50% improvement in mCAILS score at Week 12 when compared to the mCAILS score at baseline. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevat
Conditions Studied
Interventions
- DRUG Hypericin
- DRUG Mechlorethamine Topical Gel
Study Locations (1)
New York
- Rochester Skin Lymphoma Medical Group - Fairport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 2 |
What the finished NCT06149247 record still lists
NCT06149247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Cutaneous T-Cell Lymphoma/Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Hypericin is the first listed.
NCT06149247 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06149247 about?
NCT06149247 is a clinical study titled "HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL". The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
What is the current status of trial NCT06149247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-12-05. Estimated completion is 2024-06-27.
What conditions does trial NCT06149247 study?
This clinical trial studies the following conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides.
What interventions are being tested in trial NCT06149247?
The interventions under investigation include: Hypericin (DRUG), Mechlorethamine Topical Gel (DRUG).
Who is sponsoring clinical trial NCT06149247?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149247 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06149247's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI